Interpace Diagnostics Group, Inc.

(NASDAQ: IDXG)
June 16, 2017

Analyst Consensus About Interpace Diagnostics Group, Inc.

Rating1 Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and
other molecular alterations associated with gastrointestinal and endocrine cancers. The company offers Pancra-
GEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis
and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX, which assesses
thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy
utilizing a proprietary gene expression assay. Its customers consist primarily of physicians, hospitals, and clinics.
The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in
December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany,
New Jersey.

Overview Key Data

Sector Services Last Trade $1.53
Industry Business Services Price Range (52 week) 0.07 - 14.25
Full Time Employees 61 Avg Volume (13 Week) 2,038,454

Contents IPO Year N/A Shares Outstanding

Mkt Cap
8,790,000
$13,450,000
Enterprise Value N/A
Book Value per Share $3.65
1. Overview
Dividend Yield --

2. Technical Data

3. Key Ratios

4. Earnings & Analyst

5.6. Financial Statements
7. Company Insiders
8. Disclaimer
Highlights & Recent Developments
On June 05, 2017, Interpace Diagnostics Group, Inc., a fully integrated commercial
company that provides clinically useful molecular diagnostic tests and pathology
services for improved patient diagnosis and management, announced that the
Company has entered into a Laboratory Services Agreement with Einstein Medi-
cal Center of Philadelphia (Einstein) to provide expanded laboratory analytical
services to Einstein for improved identification of indeterminate thyroid nodules,
through Interpaces combined ThyGenX and ThyraMIR molecular tests.

The new Agreement provides access for Einsteins Endocrinologists, Ear Nose
and Throat physicians, and Otolaryngologists to Interpaces products for thyroid
nodules that are initially deemed indeterminate. Nationwide, approximately 20%
of thyroid nodules assessed using fine needle aspirate (FNA) biopsies are indeter-
minate and eligible for further analysis with molecular testing. The American Thy-
roid Association (ATA) has published guidelines that support the use of molecular
testing in those circumstances where traditional cytopathology is indeterminate
and unable to differentiate between malignant and benign thyroid nodules.

1
Analyst Consensus Rating based on publicly Page 1 of 7 2017 Research Driven Investing.
reported third party data. See disclaimer. All rights reserved.
 Interpace Diagnostics Group, Inc.
(NASDAQ: IDXG)
June 16, 2017

Technical Data
Price Information
52 Week Low 0.07
52 Week High 14.25
50 Day Moving Average $2.12
200 Day Moving Average $2.61
Average Daily Volume (13Wk) 2,038,454

Support / Resistance
Type Value Confluence
resist. 7.9 2
resist. 7.5 2
resist. 7.13 2
resist. 4.4 2
resist. 4.06 4
resist. 3.57 2
resist. 3.19 5
resist. 2.89 5
resist. 2.18 30

Technical Signals Indicator Signal Strength Direction

Composite Indicator Trend Spotter Sell Minimum Strengthening
7 Day Average Directional Indicator Buy Minimum Strongest
10 - 8 Day Moving Average Hilo Channel Sell Minimum Weakening
Short-Term Indicators 20 Day Moving Average vs Price Sell Weak Weakening
20 - 50 Day MACD Oscillator Sell Minimum Strongest
20 Day Bollinger Bands Hold Falling
40 Day Commodity Channel Index Sell Minimum Weakest
50 Day Moving Average vs Price Sell Minimum Weakest
Medium-Term Indicators
20 - 100 Day MACD Oscillator Sell Weak Strongest
50 Day Parabolic Time/Price Buy Minimum Strongest
60 Day Commodity Channel Index Sell Average Weakest
Long-Term Indicators 100 Day Moving Average vs Price Sell Average Strengthening
50 - 100 Day MACD Oscillator Sell Minimum Weakest

Page 2 of 7 2017 Research Driven Investing.

All rights reserved.
 Interpace Diagnostics Group, Inc.
(NASDAQ: IDXG)
June 16, 2017

Key Statistics & Ratios

Valuation Ratios
Company Industry Sector
P/E Ratio (TTM) 0.00 24.91 22.32
P/E High - Last 5 Yrs. 0.00 31.33 46.32
P/E Low - Last 5 Yrs. 0.00 14.32 13.97
Beta 1.77 0.71 0.93
Price to Sales (TTM) 0.93 576.45 16.02
Price to Book (MRQ) 0.39 3.09 2.77
Price to Tangible Book (MRQ) 0.00 4.24 5.83
Price to Cash Flow (TTM) 7.61 16.98 22.29
Price to Free Cash Flow (TTM) N/A N/A N/A
% Owned Institutions 7.9% 1.1% 1.7%

Growth Rates
Company Industry Sector
Sales (MRQ) vs Qtr. 1 Yr. Ago 14.3% 7.2% 16.7%
Sales (TTM) vs TTM 1 Yr. Ago 152.3% 9.1% 11.8%
Sales - 5 Yr. Growth Rate -39.2% 6.9% 6.7%
EPS (MRQ) vs Qtr. 1 Yr. Ago 118.8% 82.4% -236.7%
EPS (TTM) vs TTM 1 Yr. Ago 89.6% 0.0% 0.0%
EPS - 5 Yr. Growth Rate 0.0% 17.1% 10.5%
Capital Spending - 5 Yr. Growth 0.0% 5.8% 5.9%
Rate
Management Effectiveness
Financial Strength Company Industry Sector
Company Industry Sector Return On Assets (TTM) -4.9% 4.5% 4.7%
Quick Ratio (MRQ) 0.00 1.74 1.98 Return On Assets - 5 Yr. Avg. -19.6% 5.4% 4.3%
Current Ratio (MRQ) 0.82 2.09 2.37 Return On Investment (TTM) -7.2% 8.9% 6.4%
LT Debt to Equity (MRQ) 17.76 40.31 70.88 Return On Investment - 5 Yr Avg -31.7% 9.1% 6.0%
Total Debt to Equity (MRQ) 17.76 54.58 99.82 Return On Equity (TTM) -15.5% 11.3% 6.3%
Interest Coverage (TTM) -7.77 -4.24 21.52 Return On Equity - 5 Yr. Avg. -59.6% 13.1% 10.2%

Profitability Efficiency
Company Industry Sector Company Industry Sector
Gross Margin (TTM) 46.5% 30.7% 34.4% Revenue/Employee (TTM) 221,639 7,214,454
Gross Margin - 5 Yr. Avg. 20.0% 31.8% 30.6% Net Income/Employee (TTM) -41,754 921,855 31,939,554
EBITD Margin (TTM) 63.7% 0.0% 0.0% Receivable Turnover (TTM) 5.36 6.44 6.68
EBITD - 5 Yr. Avg. -9.7% 21.9% 20.0% Inventory Turnover (TTM) 0.00 40.27 64.32
Operating Margin (TTM) -3.6% 13.0% 14.8% Asset Turnover (TTM) 0.26 0.74 0.65
Operating Margin - 5 Yr. Avg. -30.7% 16.9% 13.4%
Pre-Tax Margin (TTM) -20.1% 10.5% 13.5%
Dividends
Company Industry Sector
Pre-Tax Margin - 5 Yr. Avg. -33.0% 15.3% 11.8%
Dividend Yield 0.0% 1.5% 1.5%
Net Profit Margin (TTM) -18.8% 5.9% 9.8%
Dividend Yield - 5 Year Avg. 0.0% 1.6% 1.5%
Net Profit Margin - 5 Yr. Avg. -26.9% 10.1% 8.3%
Dividend 5 Year Growth Rate 0.0% 10.4% 7.5%
Effective Tax Rate (TTM) 0.0% 30.0% 26.6%
Payout Ratio (TTM) 0.0% 20.4% 14.6%
Effective Tax Rate - 5 Yr. Avg. 0.0% 32.3% 67.7%

Page 3 of 7 2017 Research Driven Investing.

All rights reserved.
 Interpace Diagnostics Group, Inc.
(NASDAQ: IDXG)
June 16, 2017

Financial Statements
Figures in Millions of US Dollars (exept per share values)

Balance Sheet Annual Quarterly

Period Ending 31-Dec-16 31-Dec-15 31-Dec-14

Assets
Cash And Cash Equivalents 1 8 23 - - - -
Short Term Investments -- 0 0 - - - -
Net Receivables 2 3 4 - - - -
Inventory -- -- -- - - - -
Other Current Assets 1 8 18 - - - -
Total Current Assets 4 19 45 - - - -
Long Term Investments -- -- -- - - - -
Property Plant and Equipment 1 1 2 - - - -
Goodwill -- -- 16 - - - -
Intangible Assets 36 43 47 - - - -
Accumulated Amortization -- -- -- - - - -
Other Assets 0 4 6 - - - -
Deferred Long Term Asset Charges -- -- -- - - - -
Total Assets 42 68 116 - - - -

Liabilities
Accounts Payable 12 10 12 - - - -
Short/Current Long Term Debt -- 1 1 - - - -
Other Current Liabilities 4 12 22 - - - -
Total Current Liabilities 16 23 34 - - - -
Long Term Debt 8 7 27 - - - -
Other Liabilities 11 24 35 - - - -
Deferred Long Term Liability Charges -- -- -- - - - -
Total Liabilities 35 55 96 -

Stockholders Equity
Misc Stocks Options Warrants -- -- -- - - - -
Redeemable Preferred Stock -- -- -- - - - -
Preferred Stock -- -- -- - - - -
Common Stock 0 0 0 - - - -
Retained Earnings (120) (111) (100) - - - -
Treasury Stock (2) (8) (14) - - - -
Capital Surplus 128 133 134 - - - -
Other Stockholder Equity -- 0 0 - - - -
Total Stockholder Equity 7 13 20 - - - -
Net Tangible Assets (Book Value) (30) (30) (43) - - - -

Page 4 of 7 2017 Research Driven Investing.

All rights reserved.
 Interpace Diagnostics Group, Inc.
(NASDAQ: IDXG)
June 16, 2017

Income Statement Annual Quarterly

Period Ending 31-Dec-16 31-Dec-15 31-Dec-14
Total Revenue 13 9 1 -- -- -- --
Cost of Revenue 7 7 1 -- -- -- --
Gross Income 6 3 0 -- -- -- --
Research and Development 4 19 15 -- -- -- --
Selling General and Administrative 3 16 2 -- -- -- --
Non Recurring 4 4 1 -- -- -- --
Others 13 41 18 -- -- -- --
Total Operating Expenses 24 80 36 -- -- -- --
Operating Income or Loss (6) (40) (18) -- -- -- --
Total Other Income(Expenses) Net 0 (2) (0) -- -- -- --
Earnings Before Interest And Taxes (6) (41) (18) -- -- -- --
Interest Expense 2 4 1 -- -- -- --
Income Tax Expense (9) (44) (18) -- -- -- --
Net Income From Continuing Ops (8) (31) (13) -- -- -- --
Other Items not from Continuing Operations -- -- -- -- -- -- --
Net Income attributable to the Company (8) (11) (16) -- -- -- --
Preferred Stock And Other Adjustments -- -- -- -- -- -- --
Net Income Applicable To Common Shares (8) (11) (16) -- -- -- --

Cash Flow Statement Annual Quarterly

Period Ending 31-Dec-16 31-Dec-15 31-Dec-14
Net Income (8) (11) (16) -- -- -- --

Operating Activities
Depreciation 7 6 3 -- -- -- --
Adjustments To Net Income (7) (8) 1 -- -- -- --
Changes In Accounts Receivables 5 (6) (3) -- -- -- --
Changes In Liabilities (9) (7) (5) -- -- -- --
Changes In Inventories -- -- -- -- -- -- --
Changes In Other Operating Activities 4 6 4 -- -- -- --
Total Cash Flow From Operating Activities (9) (20) (16) -- -- -- --
Investing Activities
Capital Expenditures -- (0) (3) -- -- -- --
Investments -- -- (1) -- -- -- --
Other Cash flows from Investing Activities -- 27 (22) -- -- -- --
Total Cash Flows From Investing Activities -- 26 (25) -- -- -- --

Financing Activities
Dividends Paid -- -- -- -- -- -- --
Sale Purchase of Stock 2 0 (0) -- -- -- --
Net Borrowings -- (20) (20) -- -- -- --
Other Cash Flows from Financing Activities (0) (2) 20 -- -- -- --
Total Cash Flows From Financing Activities 1 (21) 19 -- -- -- --
Effect Of Exchange Rate Changes -- -- -- -- -- -- --
Other Liabilities 11 24 35 - - - -

Page 5 of 7 2017 Research Driven Investing.

All rights reserved.
 Interpace Diagnostics Group, Inc.
(NASDAQ: IDXG)
June 16, 2017

Company Insiders

Company Officers
Name Age Since Current Position Basic Compensation Options Options Value
Stephen Sullivan 69 2016 Chairman of the Board -- -- --
Jack Stover 63 2016 President, Chief Executive Officer, Director $116,299 -- --
James Early 62 2016 Chief Financial Officer, Principal Financial Officer, -- -- --
Principal Accounting Officer
Joseph Keegan 62 2016 Independent Director -- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --
-- -- --

Insider Transactions
Trading Date Name Title Type Shares Traded Price
2 Feb 2016 Stover (Jack E) Chief Executive Officer Buy 100000 $0.53
2 Feb 2016 Glorikian (Harry) Director Buy 127696 $0.47
2 Feb 2016 Sullivan (Stephen J) Director Buy 100000 $0.47
2 Feb 2016 Keegan (Joseph D) Director Buy 127696 $0.47
27 Dec 2015 Miao (Graham G) Chief Financial Officer Sell 69020 $0.53
30 Nov 2015 Melillo (Gerald R Jr) Officer Sell 1748 $0.77
29 Nov 2015 Melillo (Gerald R Jr) Officer Sell 765 $0.80
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --
-- -- -- -- -- --

Page 6 of 7 2017 Research Driven Investing.

All rights reserved.
 Interpace Diagnostics Group, Inc.
(NASDAQ: IDXG)
June 16, 2017

Disclaimer

This report is provided for general information purposes only. The information contained in this report is not to
be construed as advice and should not be confused as any sort of advice. Information has been obtained from
sources considered to be reliable, but we do not guarantee the information is accurate, correct, complete, or
timely or make any warranties regarding results from its usage. Past performance is not a guarantee of future re-
sults. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. Redis-
tribution or reproduction is prohibited without written permission.

Research Driven Investing / RDInvesting.com (hereafter RDI) is an online financial newsletter focused on coverage of
small-cap and large-cap public companies. RDI is not a registered broker dealer or a registered investment advisor. No
information accessed through the RDI Web site or this report constitutes a recommendation or solicitation to buy, sell or
hold any security in any jurisdiction.

All bullish, bearish, neutral or other analyst ratings are based on publically available third party analyst ratings. Specifical-
ly, both the Analyst Consensus Rating and Current Analyst Consensus Data are directly based on information published
by money.msn.com.

RDI receives compensation from third party organizations for advertising services provided in the form of email newslet-
ters. RDI and its affiliates, officers, directors and agents have been compensated for featured company coverage and
therefore information should not be construed as unbiased.

RDI and its outside sources use certain data derived from the U.S. Securities and Exchange Commission (SEC) filings,
public information and data compiled by other vendors. The reader should verify all claims and do his/her own research
and due diligence before investing in any securities mentioned. Visitors to www.rdinvesting.com , readers of RDI s distrib-
uted reports/releases/advertisements, and other interested parties assume full responsibility for the accuracy of all SEC
filing data, compiled data from other sources including data from the issuing Company, and are urged to confirm that data
with the specific issuing Company. RDI will not be liable to any person or entity for the quality, accuracy, completeness,
reliability or timeliness of information in this report, or for any direct, indirect, consequential, incidental, special or punitive
damages that may arise out of the use of information, products or services from any person or entity including but not
limited to lost profits, loss of opportunities, trading losses, and damages that may result from any incompleteness or inac-
curacy in the profiled company information RDI and its data vendors do not assume any responsibility or liability for any
investor decision made as a result of accessing fundamental and/or financial data on any profiled company as a conse-
quence of viewing our materials. RDI encourages its readers and visitors to its website to invest carefully and read the
investor information available on the web sites of the Securities and Exchange Commission (SEC) at www.sec.gov and/
or the National Association of Securities Dealers (NASD) at www.nasd.com. Investors interested in purchasing securities
are advised to read the Prospectus, 10K, 10Q, other relevant public documents in full, request Company financial informa-
tion and to conduct their own research and due diligence.

Statements made in this release may include projections, made in reliance on the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. RDI has made every reasonable effort to ensure that the information and as-
sumptions on which these statements and projections are based are current, reasonable, and complete. However, a vari-
ety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations
expressed in this release. RDI makes these statements and projections in good faith, neither RDI nor its management can
guarantee that the transactions will be consummated or that anticipated future results will be achieved.

Page 7 of 7 2017 Research Driven Investing.

All rights reserved.